Biography – Craig Jenkins

Director - Product Quality Monitoring

Canadian Blood Services
1800 Alta Vista
Ottawa, ON K1G 4J5

Phone: 613-739-2427
E-mail: craig.jenkins@blood.ca

• Product Quality Monitoring

The Quality Monitoring Program (QMP) is a natural extension of the activities of the Development Program of Research & Development (R&D). This program further integrates the R&D group into CBS activities; it enhances the problem solving skills of the organization and better aligns CBS with Industry Best Practices. The Quality Monitoring Program serves two main functions. The first is heightened surveillance of product function beyond the measurements of the current quality control standards. The second is to act as a centralized trouble shooting group for the organization. The program, operating closely with NetCAD can co-ordinate the interaction of R&D subject matter experts with 'Operations' and 'QA&RA' and other departments to ensure timely and accurate resolution to primarily manufacturing issues. The initiative endeavors to provide information necessary to set new standards for blood and blood components as well as to utilize opportunities for improvement, especially with respect to opportunities for efficiencies, to enhance manufacturing capabilities to produce the best possible blood products.

While all areas of the R&D program offers a potential source of scientific expertise, three specific sites have been selected on the basis of relationship to each of our three main manufactured blood components as the primary supporters of the quality monitoring program. Vancouver, Edmonton and Hamilton sites provide the primary expert knowledge and support in the areas of Platelets, Red Blood Cells and Plasma respectively.

As the Director of the Quality Monitoring Program I am responsible for the daily and strategic activities of the program. Additional to the above responsibilities there is also contact with international colleagues involved in the quality monitoring of blood products to ensure CBS stays abreast with industry best practices.

Selected Publications:

Levin E, Culibrk B, Gyongyossy-Issa MIC, Weiss S, Scammell K, LeFresne W, Jenkins C, Devine DV. Implementation of buffy coat platelet component production: Comparison to platelet-rich plasma platelet production. Transfusion 48: 2331-7 (2008)

Ramirez-Arcos S, Jenkins C, Dion J, Bernier F, Delage G, Goldman M. Canadian Experience with detection of bacterial contamination in apheresis platelets. Transfusion 2007; 47: 421-9.